on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Files 2024 Universal Registration Document
GenSight Biologics, a biopharma firm specializing in gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has announced the filing of its 2024 Universal Registration Document. The document was submitted on April 7, 2025, to the French market authority, AMF. This follows the company's focus on advancing innovative treatments for vision preservation and restoration.
The Universal Registration Document encompasses several key sections, including the 2024 annual financial report, management report, a report on corporate governance, and details of the share buyback program. These components provide a comprehensive overview of the company's operations and strategic objectives for stakeholders and potential investors.
Individuals interested in reviewing these documents can access them on the official website of GenSight Biologics or through the AMF's platform, reinforcing the company's commitment to transparency and investor relations.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news